Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer's disease

Front Pharmacol. 2023 Oct 6:14:1239060. doi: 10.3389/fphar.2023.1239060. eCollection 2023.

Yunxia Luo^#^{1

2}, Dongli Li^#¹, Yanfang Liao^#¹, Chuipu Cai¹, Qihui Wu¹, Hanzhong Ke^{3

4}, Xinning Liu¹, Huilin Li², Honghai Hong⁵, Yumin Xu⁶, Qi Wang^{1

7}, Jiansong Fang^{1

7}, Shuhuan Fang^{1

7}

¹ Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
² Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
³ Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States.
⁴ Department of Medicine, Harvard Medical School, Boston, MA, United States.
⁵ Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
⁶ Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
⁷ Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fphar.2020.00381.].

Keywords: Alzheimer’s disease; Kai-Xin-San; cholinergic system; neuroinflammation; systems pharmacology.